Key result
VerifyNow-P2Y12 correlates with VASP in clopidogrel-treated ACS but shows discordance with ADP-induced aggregation.
Why the study?
Does the VerifyNow-P2Y12 device correlate with the VASP phosphorylation assay and platelet aggregometry in ACS patients treated with clopidogrel?
Observational (n=81)
No
Does the VerifyNow-P2Y12 device correlate with the VASP phosphorylation assay and platelet aggregometry in ACS patients treated with clopidogrel?
The VerifyNow-P2Y12 point-of-care device provides results comparable to the VASP assay for assessing clopidogrel response in ACS patients, offering a rapid and easy alternative.
Answers are grounded in this paper and cite their sources.
Supports VerifyNow-P2Y12 as rapid VASP alternative in ACS on clopidogrel; leaves open discordance with aggregometry and clinical utility.
Point-of-care testing permits an evaluation of the efficacy of drugs used in the treatment of acute coronary syndromes (ACS). An increased risk of thrombosis after coronary stenting for ACS patients treated with aspirin and clopidogrel has been linked to high platelet reactivity and, for certain patients, poor drug response. The objective of our study was to compare the VerifyNow-P2Y12 device with the VASP (vasodilator-stimulated phosphoprotein) phosphorylation assay and ADP-induced platelet aggregation as assessed by light transmission aggregometry in a group of 81 ACS patients (100 tests) treated in our hospital. There was a good correlation between VerifyNow-P2Y12 and VASP especially during the chronic phase of one month or more after the ischemic event, whereas discordance was sometimes seen with platelet aggregometry. The rapidity and ease of use of the VerifyNow device suggests that it has a valuable place in point-of-care testing of ACS patients.
No takes yet. Share an insight, caveat, or question.
Bidet et al. (2010) conducted an observational in Acute coronary syndromes (ACS) (n=81). VerifyNow-P2Y12 device vs. VASP phosphorylation assay and ADP-induced platelet aggregation was evaluated on Correlation between VerifyNow-P2Y12, VASP, and ADP-induced platelet aggregation. The VerifyNow-P2Y12 device showed good correlation with the VASP assay in ACS patients on clopidogrel, but sometimes showed discordance with ADP-induced platelet aggregation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: